CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

Groups of districts already working on escaping the factory model applied for grant money to work on innovative high school options.

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The global sales of DNA polymerase are estimated to be worth USD 397.7 million in 2025 and anticipated to reach a value of ...